Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb 1;82(5):1004–1008. doi: 10.1054/bjoc.1999.1033

Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume

M M Davies 1, S K Jonas 1, S Kaur 1, T G Allen-Mersh 1
PMCID: PMC2374421  PMID: 10737380

Abstract

The extent to which plasma levels of angiogenic factors in healthy individuals and tumour volume-related variations in colorectal cancer affect the accuracy of circulating angiogenic factors as predictors of colorectal cancer vascularity is unknown. We used enzyme-linked immunosorbant assay to measure plasma vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) levels in colorectal liver metastasis (CLM) patients, and ‘no cancer’ controls. CLM volume was determined from computerized tomography scans, and tumour vessel count and vessel volume from anti-endothelial antibody-stained biopsies. There was a significant (P = 0.03) increase in plasma VEGF level in 29 CLM patients (median 180.3 pg ml−1, iqr 132.5–284.8 pg ml−1) compared with 19 controls (median 125.8 pg ml−1, iqr 58.2–235.9 pg ml−1). There were significant correlations between plasma VEGF and tumour vessel count (r = 0.66, P = 0.03), tumour vessel volume (r = 0.59, P = 0.03), and CLM volume (r = 0.53, P = 0.03). A VEGF level in the upper quartile of the plasma VEGF distribution had a 70% sensitivity and 75% specificity in predicting an upper quartile liver metastasis tumour vessel count. No relation was identified between CLM and plasma bFGF levels. Plasma VEGF level predicted CLM vascularity, despite an overlap with normal levels and tumour volume-related variations. © 2000 Cancer Research Campaign

Keywords: colorectal cancer, VEGF, bFGF, angiogenesis, tumour volume

Full Text

The Full Text of this article is available as a PDF (65.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen-Mersh T. G., Earlam S., Fordy C., Abrams K., Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994 Nov 5;344(8932):1255–1260. doi: 10.1016/s0140-6736(94)90750-1. [DOI] [PubMed] [Google Scholar]
  2. Banks R. E., Forbes M. A., Kinsey S. E., Stanley A., Ingham E., Walters C., Selby P. J. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998 Mar;77(6):956–964. doi: 10.1038/bjc.1998.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–165. doi: 10.1016/s0065-230x(08)60305-x. [DOI] [PubMed] [Google Scholar]
  4. Dirix L. Y., Vermeulen P. B., Hubens G., Benoy I., Martin M., De Pooter C., Van Oosterom A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol. 1996 Oct;7(8):843–848. doi: 10.1093/oxfordjournals.annonc.a010764. [DOI] [PubMed] [Google Scholar]
  5. Dirix L. Y., Vermeulen P. B., Pawinski A., Prové A., Benoy I., De Pooter C., Martin M., Van Oosterom A. T. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer. 1997;76(2):238–243. doi: 10.1038/bjc.1997.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dworkin M. J., Burke D., Earlam S., Fordy C., Allen-Mersh T. G. Measurement of response to treatment in colorectal liver metastases. Br J Cancer. 1995 Apr;71(4):873–876. doi: 10.1038/bjc.1995.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eisma R. J., Spiro J. D., Kreutzer D. L. Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg. 1997 Nov;174(5):513–517. doi: 10.1016/s0002-9610(97)00166-9. [DOI] [PubMed] [Google Scholar]
  8. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4–6. doi: 10.1093/jnci/82.1.4. [DOI] [PubMed] [Google Scholar]
  9. Fox S. B., Leek R. D., Weekes M. P., Whitehouse R. M., Gatter K. C., Harris A. L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol. 1995 Nov;177(3):275–283. doi: 10.1002/path.1711770310. [DOI] [PubMed] [Google Scholar]
  10. Fujimoto K., Ichimori Y., Kakizoe T., Okajima E., Sakamoto H., Sugimura T., Terada M. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun. 1991 Oct 15;180(1):386–392. doi: 10.1016/s0006-291x(05)81305-1. [DOI] [PubMed] [Google Scholar]
  11. Fujisaki K., Mitsuyama K., Toyonaga A., Matsuo K., Tanikawa K. Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol. 1998 Feb;93(2):249–252. doi: 10.1111/j.1572-0241.1998.00249.x. [DOI] [PubMed] [Google Scholar]
  12. Gasparini G., Harris A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol. 1995 Mar;13(3):765–782. doi: 10.1200/JCO.1995.13.3.765. [DOI] [PubMed] [Google Scholar]
  13. Kondo S., Asano M., Matsuo K., Ohmori I., Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta. 1994 Mar 31;1221(2):211–214. doi: 10.1016/0167-4889(94)90016-7. [DOI] [PubMed] [Google Scholar]
  14. Kumar H., Heer K., Lee P. W., Duthie G. S., MacDonald A. W., Greenman J., Kerin M. J., Monson J. R. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res. 1998 May;4(5):1279–1285. [PubMed] [Google Scholar]
  15. Landriscina M., Cassano A., Ratto C., Longo R., Ippoliti M., Palazzotti B., Crucitti F., Barone C. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer. 1998 Sep;78(6):765–770. doi: 10.1038/bjc.1998.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989 Dec 8;246(4935):1306–1309. doi: 10.1126/science.2479986. [DOI] [PubMed] [Google Scholar]
  17. Maeda K., Chung Y. S., Ogawa Y., Takatsuka S., Kang S. M., Ogawa M., Sawada T., Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996 Mar 1;77(5):858–863. doi: 10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  18. Mayers M. M., Seshadri R., Raymond W., McCaul K., Horsfall D. J. Tumor microvascularity has no independent prognostic significance for breast cancer. Pathology. 1998 May;30(2):105–110. doi: 10.1080/00313029800169046. [DOI] [PubMed] [Google Scholar]
  19. Meyer G. E., Yu E., Siegal J. A., Petteway J. C., Blumenstein B. A., Brawer M. K. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer. 1995 Dec 1;76(11):2304–2311. doi: 10.1002/1097-0142(19951201)76:11<2304::aid-cncr2820761119>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  20. Senger D. R., Van de Water L., Brown L. F., Nagy J. A., Yeo K. T., Yeo T. K., Berse B., Jackman R. W., Dvorak A. M., Dvorak H. F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993 Sep;12(3-4):303–324. doi: 10.1007/BF00665960. [DOI] [PubMed] [Google Scholar]
  21. Sliutz G., Tempfer C., Obermair A., Dadak C., Kainz C. Serum evaluation of basic FGF in breast cancer patients. Anticancer Res. 1995 Nov-Dec;15(6B):2675–2677. [PubMed] [Google Scholar]
  22. Sliutz G., Tempfer C., Obermair A., Reinthaller A., Gitsch G., Kainz C. Serum evaluation of basic fibroblast growth factor in cervical cancer patients. Cancer Lett. 1995 Aug 1;94(2):227–231. doi: 10.1016/0304-3835(95)03853-o. [DOI] [PubMed] [Google Scholar]
  23. Takahashi Y., Kitadai Y., Bucana C. D., Cleary K. R., Ellis L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995 Sep 15;55(18):3964–3968. [PubMed] [Google Scholar]
  24. Terayama N., Terada T., Nakanuma Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue. Histopathology. 1996 Jul;29(1):37–43. doi: 10.1046/j.1365-2559.1996.d01-484.x. [DOI] [PubMed] [Google Scholar]
  25. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol. 1998 Feb;184(2):119–122. doi: 10.1002/(SICI)1096-9896(199802)184:2<119::AID-PATH17>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  26. Yamamoto S., Konishi I., Mandai M., Kuroda H., Komatsu T., Nanbu K., Sakahara H., Mori T. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 1997;76(9):1221–1227. doi: 10.1038/bjc.1997.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yamamoto Y., Toi M., Kondo S., Matsumoto T., Suzuki H., Kitamura M., Tsuruta K., Taniguchi T., Okamoto A., Mori T. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res. 1996 May;2(5):821–826. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES